Select Publications
Journal articles
2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 73, pp. E107 - E118, http://dx.doi.org/10.1093/cid/ciaa612
,2021, 'Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs', International Journal of Drug Policy, 93, http://dx.doi.org/10.1016/j.drugpo.2020.102908
,2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, 6, pp. 533 - 546, http://dx.doi.org/10.1016/S2468-1253(21)00077-7
,2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571
,2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, 18, http://dx.doi.org/10.1371/journal.pmed.1003656
,2021, 'The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits Scheme', JGH Open, 5, pp. 813 - 819, http://dx.doi.org/10.1002/jgh3.12593
,2021, 'Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia', The Lancet Regional Health - Western Pacific, 12, http://dx.doi.org/10.1016/j.lanwpc.2021.100193
,2021, 'Australian COVID-19 response: Lessons and future directions', Journal and Proceedings of the Royal Society of New South Wales, 154, pp. 78 - 84
,2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, 72, pp. E649 - E651, http://dx.doi.org/10.1093/cid/ciaa1256
,2021, 'Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival', Journal of Viral Hepatitis, 28, pp. 710 - 718, http://dx.doi.org/10.1111/jvh.13475
,2021, 'The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting', Addiction, 116, pp. 1162 - 1171, http://dx.doi.org/10.1111/add.15277
,2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253
,2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963
,2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, 223, pp. 818 - 826, http://dx.doi.org/10.1093/infdis/jiaa442
,2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, http://dx.doi.org/10.1093/infdis/jiaa442
,2021, 'Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive', Clinical Infectious Diseases, 72, pp. 753 - 754, http://dx.doi.org/10.1093/cid/ciaa138
,2021, 'Retraction notice to: USP1 regulates cellular senescence by controlling genomic integrity (Cell Reports (2016) 15(7) (1401–1411), (S2211124716304466), (10.1016/j.celrep.2016.04.033))', Cell Reports, 34, http://dx.doi.org/10.1016/j.celrep.2021.108786
,2021, 'Author Correction: Hepatitis C virus elimination: laying the foundation for achieving 2030 targets (Nature Reviews Gastroenterology & Hepatology, (2021), 18, 2, (91-92), 10.1038/s41575-020-00392-3)', Nature Reviews Gastroenterology and Hepatology, 18, pp. 143, http://dx.doi.org/10.1038/s41575-020-00407-z
,2021, 'Hepatitis C virus elimination: laying the foundation for achieving 2030 targets', Nature Reviews Gastroenterology and Hepatology, 18, pp. 91 - 92, http://dx.doi.org/10.1038/s41575-020-00392-3
,2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038
,2021, 'Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas', The Lancet Gastroenterology and Hepatology, 6, pp. 89 - 90, http://dx.doi.org/10.1016/S2468-1253(20)30371-X
,2021, 'Elimination of hepatitis c in australia by 2030: A decade and counting', Australian Prescriber, 44, pp. 36 - 37, http://dx.doi.org/10.18773/austprescr.2021.003
,2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 6, pp. 39 - 56, http://dx.doi.org/10.1016/S2468-1253(20)30303-4
,2021, 'Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or ‘re-diagnose’ infections is effective in Australia', Journal of Viral Hepatitis, 28, pp. 121 - 128, http://dx.doi.org/10.1111/jvh.13393
,2021, 'Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection', , http://dx.doi.org/10.1101/2021.06.01.21257759
,2021, 'Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort', , http://dx.doi.org/10.1101/2021.03.29.21254211
,2020, 'SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants', , http://dx.doi.org/10.1101/2020.12.19.20248567
,2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, 222, pp. S758 - S772, http://dx.doi.org/10.1093/infdis/jiaa366
,2020, 'We must do better: Addressing HCV treatment barriers in persons who inject drugs in the United States', Journal of Infectious Diseases, 222, pp. S773 - S781, http://dx.doi.org/10.1093/infdis/jiaa574
,2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', The Lancet Gastroenterology and Hepatology, 5, pp. 1028 - 1029, http://dx.doi.org/10.1016/S2468-1253(20)30270-3
,2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
,2020, 'Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C', Liver International, 40, pp. 2353 - 2355, http://dx.doi.org/10.1111/liv.14661
,2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985
,2020, 'Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy', International Journal of Drug Policy, 83, pp. 102837, http://dx.doi.org/10.1016/j.drugpo.2020.102837
,2020, 'People with hepatitis C who inject drugs — Underserved, not undeserving', New England Journal of Medicine, 383, pp. 608 - 611, http://dx.doi.org/10.1056/NEJMp2002126
,2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, 73, pp. S127 - S127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587000206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR', JOURNAL OF HEPATOLOGY, 73, pp. S356 - S356, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587001105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study', BMJ Open, 10, pp. e034389, http://dx.doi.org/10.1136/bmjopen-2019-034389
,2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
,2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
,2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151
,2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
,2020, 'Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance', Hepatology Communications, 4, pp. 904 - 915, http://dx.doi.org/10.1002/hep4.1496
,2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
,2020, 'Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation', Gastroenterology Clinics of North America, 49, pp. 253 - 277, http://dx.doi.org/10.1016/j.gtc.2020.01.005
,2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8
,2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584
,2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
,2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
,